Core Viewpoint - The approval of the clinical trial application for M701, a bispecific antibody targeting EpCAM and CD3, marks a significant advancement in the international clinical development of a novel therapy for malignant pleural effusion (MPE), providing new hope for patients globally [1] Group 1: Product Development - The clinical trial for M701 has been approved by the U.S. Food and Drug Administration (FDA) and is set to begin on January 31, 2026 [1] - M701 specifically targets EpCAM and CD3, with EpCAM being highly expressed in tumor cells associated with malignant pleural effusion, making it a critical therapeutic target [1] - The trial is an open-label, multicenter, Phase Ib/II study aimed at evaluating the safety, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of M701 in patients with advanced epithelial tumors causing malignant pleural effusion [1] Group 2: Market Need - Malignant pleural effusion is a common and severe complication of malignant tumors, particularly in late-stage lung and breast cancer patients, highlighting the urgent need for innovative treatment strategies to fill clinical gaps [1] - Current treatment approaches primarily focus on palliative care, indicating a significant opportunity for new therapeutic options in this area [1]